Studio for CROs

Within biosample storage, a “nightmare scenario” exists that Medable and our clients discuss regularly.

Some years ago, a sponsor with tens of thousands of biosample specimens identified that they had lost the ability to link their biobank samples' documented consent for storage (and further research). The consent for these samples was taken on paper, but a system to collate and file the consent data attributed to each specimen was not implemented. When the organization couldn’t find the paper consent, they were forced to dispose of thousands of biospecimens, losing the ability to conduct valuable research and potentially millions of dollars of lost IP.

‍

In Medable’s first edition of Evidence and Insights, you’ll get an in-depth look at our research investments and collaborations exploring the effects of DCTs and clinical research technology. Through strategic partnerships and continued investment, we’ve spearheaded efforts that redefine industry standards and set a new precedent for the evidentiary basis of technology’s impact on drug development.

‍

‍

With the share of oncology trials continuing to increase, the case for using digital tools in these trials grows with it.

Today, cancer trials are the most commonly researched of all diseases, with their share of clinical trials growing each year. According to research from Tufts CSDD,  the number of cancer drugs “has nearly quadrupled since 2000, to 1,489 trials in 2021, up from 421 two decades earlier.”

Tufts CSDD notes that this growth comes as “oncology drug developers are increasingly shifting toward precision medicine, embracing new molecular targets and improvements in genetic sequencing technologies”

‍